The study will enroll approximately 30 patients. All participants will receive a single 40 mg dose of MLN0128 capsules on Day 1. To avoid nausea and vomiting, participants will also be administered 0.25 mg palonosetron on Day 1 as an antiemetic agent. Participants may continue to receive MLN0128 for up to 1 year at a dose of up to 30 mg once weekly if a clinical benefit is being derived.